Genetic variations of NLRP1: susceptibility in psoriasis

被引:70
作者
Ekman, A. -K. [1 ]
Verma, D. [1 ]
Fredrikson, M. [2 ]
Bivik, C. [1 ]
Enerback, C. [1 ]
机构
[1] Linkoping Univ, Fac Hlth Sci, Ingrid Asp Psoriasis Res Ctr, SE-58185 Linkoping, Sweden
[2] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Div Occupat & Environm Med, SE-58185 Linkoping, Sweden
关键词
CUTANEOUS ANGIOSARCOMA; DOCETAXEL TAXOTERE; SOFT-TISSUE; PACLITAXEL; SCALP; CANCER; RADIATION; FACE; TAXOL;
D O I
10.1111/bjd.13178
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background NACHT, LRR and PYD domain-containing protein (NLRP) 1 is part of the inflammasome multiprotein complex involved in the production of interleukin (IL)-1 beta and IL-18, two cytokines strongly implicated in psoriasis pathogenesis. Genetic variations in NLRP1 are associated with a predisposition for chronic inflammatory conditions. Objectives The aim of the study was to investigate the role of genetic variation in the NLRP1 inflammasome in psoriasis susceptibility. Material and methods Four haplotype-tagging single-nucleotide polymorphisms (SNPs) (rs6502867, rs8079034, rs878329 and rs12150220) were investigated by TaqMan allelic discrimination in a patient sample comprising 1847 individuals from 478 families and 802 healthy controls. Results Using the transmission disequilibrium test, a significant increase in the transmission of the NLRP1 rs8079034C and rs878329C alleles to patients with psoriasis was demonstrated (P = 0.006 and P = 0.033, respectively). Furthermore, homozygosity for the rs878329C allele correlated with a younger age of onset. We also observed an increase in the expression of NLRP1 mRNA in the peripheral blood cells of patients with psoriasis. This was accompanied by a higher level of circulating IL-18 and appeared to be associated with the rs878329C allele. Conclusions Our data support the involvement of NLRP1 and the NLRP1 inflammasome in psoriasis susceptibility and further support the role of innate immunity in psoriasis.
引用
收藏
页码:1517 / 1520
页数:4
相关论文
共 29 条
[1]   Treatment and outcome of 82 patients with angiosarcoma [J].
Abraham, John A. ;
Hornicek, Francis J. ;
Kaufman, Adam M. ;
Harmon, David C. ;
Springfield, Dempsey S. ;
Raskin, Kevin A. ;
Mankin, Henry J. ;
Kirsch, David G. ;
Rosenberg, Andrew E. ;
Nielsen, G. Petur ;
Desphpande, Vikram ;
Suit, Herman D. ;
DeLancy, Thomas F. ;
Yoon, Sam S. .
ANNALS OF SURGICAL ONCOLOGY, 2007, 14 (06) :1953-1967
[2]  
Cerrotta A, 2002, EUR J GYNAECOL ONCOL, V23, P115
[3]  
Creane M, 1999, INT J RADIAT BIOL, V75, P731, DOI 10.1080/095530099140078
[4]   Risk-adapted, dose escalation study of weekly docetaxel in the first-line treatment of elderly patients with advanced cancer [J].
Culine, Stephane ;
Terret, Catherine ;
Cupissol, Didier ;
Romieu, Gilles ;
Fabbro, Michel ;
Pouessel, Damien ;
Droz, Jean-Pierre ;
Gourgou, Sophie .
JOURNAL OF GERIATRIC ONCOLOGY, 2013, 4 (02) :122-127
[5]  
Espat N J, 2000, Sarcoma, V4, P173, DOI 10.1080/13577140020025896
[6]  
Fata F, 1999, CANCER-AM CANCER SOC, V86, P2034, DOI 10.1002/(SICI)1097-0142(19991115)86:10<2034::AID-CNCR21>3.3.CO
[7]  
2-G
[8]   Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer [J].
Fennelly, D ;
Aghajanian, C ;
Shapiro, F ;
OFlaherty, C ;
McKenzie, M ;
OConnor, C ;
Tong, W ;
Norton, L ;
Spriggs, D .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (01) :187-192
[9]   Comparison between taxane-based chemotherapy with conventional surgery-based therapy for cutaneous angiosarcoma: a single-center experience [J].
Fujisawa, Yasuhiro ;
Nakamura, Yasuhiro ;
Kawachi, Yasuhiro ;
Otsuka, Fujio .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2014, 25 (05) :419-423
[10]  
Fuller Christopher K, 2010, J Am Acad Dermatol, V63, pe83, DOI 10.1016/j.jaad.2009.09.035